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Abstract
Lung cancer has been considered one of the leading causes of deaths while cancer re-
mains the second most common cause of deaths in the USA. Understanding the behavior of
a disease over time could yield important information to make decisions about the disease.
Statistical models could provide crucial clues and help to make a decision about the dis-
ease, budget allocation, evaluation, and implement prevention. Longitudinal trend analysis
of the diseases helps to understand long term effects and nature. Cholesterol level is one of
the most contributing risk factors for Coronary Heart Disease. Studying cholesterol statis-
tically helps to know more about its nature and provides crucial information to mitigate its
effectiveness in diagnosing its impact to public health.
In our study, we have analyzed lung cancer mortality in the USA based on age at death,
period at death, and birth cohort to investigate its nature in longitudinal effects. The attempt
has been made to estimate mortality rate based on age for different age groups and to find
the relative risk of mortality due to period effect and relative risk due to birth cohort for
lung cancer in the United States. Our statistical analysis and modeling are based on the data
obtained from Surveillance Epidemiology and End Results (SEER) program of the United
States.
We have also investigated the probabilistic behavior of average cholesterol level based
on gender and ethnicity. The study reveals significant differences with respect to the distri-
bution they follow and their basic inferences which could be beneficial to draw conclusions
in various ways in addressing related issues. At the same time, the change of cholesterol
level over time for an individual might be a good source to study the association of choles-
terol level, coronary heart disease and their effects on age. The cholesterol data is obtained
vi
from inter-university Consortium for Political and Social Research and National Health and
Nutrition Examination Survey (NHANS) of the United States.
Understanding the average change in total serum cholesterol level over time as people
get older could be vital to explore it. We have studied the longitudinal behavior of the
association of sex and time with cholesterol level. It is observed that age, sex, and time
have an individual effect and can impact differently upon collective considerations. Their
adverse effect in increasing cholesterol level could promote to worsen the cholesterol re-
lated issues and hence heart related diseases. We believe our study pivots knowing more
about target population of cholesterol level and helps to have the useful inference about
cholesterol levels for public health.
Finally, we also analyzed the average cholesterol data using a functional data analysis
approach to understand its nature and effect on age. Since functional data analysis approach
presents more flexibility in modeling, it could provide more insight in studying cholesterol
level.
vii
Chapter 1
Introduction
In this chapter we briefly discuss some of the statistical methods, algorithms and estimation
procedures that we used in the present studies.
Mortality due to lung cancer in the United States is really alarming with respect to public
health safety. It is one of the major causes of cancer deaths, where cancer alone is approach-
ing the number one cause of deaths in the USA. Analyzing cancer deaths over time might
provide important clues to the epidemiologists, public health practitioners, and decision
makers about the disease to better understand its nature and efficacy of past decisions.
Lung cancer has been considered the second most commonly diagnosed cancer among
men and women in the United States [1, 2]. In our second chapter, we have estimated the
lung cancer mortality rate based on different five year age groups from median age 22 years
to 82 years from 1971 to 2010, the most recent data available for the USA. We have also
estimated the relative risk due to period effects and due to birth cohort of lung cancer for
the USA. Most of Chapter Two has already been published in the journal “Epidemiology
Biostatistics and Public Health” [3].
Normality assumption may not always be the case to study the behavior of the phe-
nomenon we are interested in. In the third chapter, we investigate total cholesterol level of
an individual based on gender and race to better understand it probabilistically. Parametric
analysis can perform well with skewed and non normal distributions when the data follow
a particular distribution. Basic properties of distribution could reveal basic but crucial in-
formation about the cholesterol level we are interested in.
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To characterize changes in cholesterol level over time and to investigate between and
within subject variations, a longitudinal study appears to be useful. Linear mixed model
approach is considered a popular procedure for analyzing repeated measures and clustered
data. Its application is wide including biology, epidemiology, economics, etc. In the fourth
chapter, we have investigated the total cholesterol level of individuals to better understand
how it changes over time, as age, gender, and time are considered to be risk factors. Fi-
nally, we have also investigated average cholesterol level through a functional data analysis
approach where data are transformed into a curve considered as basis functions. It pro-
vides more flexibility in modeling and smoothing the data. Most of this chapter has been
accepted for publication as proceeding of Dynamic Systems and Application [4].
1.1 Generalized Linear Model (GLM)
The generalized linear model (GLM) is an extension of the linear model framework to
variables that are not normally distributed. A generalization of linear models that connects
the random distribution of the dependent variable (the distribution function) to the linear
predictor-effect through a link function. It is a nice way of unifying various statistical mod-
els, like linear regression, logistic regression, and Poisson regression, etc, under a single
framework. If the distributions of observations are or can be approximated with the normal
distribution, the linear models are useful. Even if it is not the case, normal distribution
is a safe assumption for large samples. However, a non-linear model should be used for
many cases where linear models are not appropriate, such as when response is restricted
to binary or count and variance of response depends on the mean. GLM extends the linear
model framework to address both of these issues. There are three basic components of a
generalized linear model. The components are:
1. A random component that specifies the conditional distribution of the response variable
given the values of the explanatory variables. The response variables are assumed to
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have the same distribution that is coming from the exponential family of distributions.
2. A systematic component (design matrix multiplied by parameter vector).
3. A smooth and invertible mathematical function, called the link function that links the
systematic component to the random component.
1.2 Bayesian Model Selection Criteria
In this section we briefly introduce the deviance data criteria that we use in the model
selection process.
1.2.1 Deviance Information Criteria
The deviance information criterion (DIC)[5] is a measure of model comparison and ade-
quacy. It is given by
DIC(m) = 2D(θm,m)−D(θ¯m,m) = D(θ¯m,m) + 2pm (1.1)
whereD(θm,m) is the usual deviance measure and is given byD(θm,m) = −2logf(y|θm,m)
and D(θm,m) is its posterior mean. pm can be taken as the number of effective parameters
for the model m given by pm = D(θm,m)−D(θ¯m,m). θ¯m is posterior mean of the param-
eters involved in model m. The smaller the DIC, the better fitting the model. The DIC is
approximately equal to Akaike’s information criterion (AIC)[6]. It is important to note that
the DIC should not be used when the posterior distributions are highly skewed or bimodal
since it assumes symmetry.
1.3 Markov Chain Monte Carlo Method (MCMC)
Evaluating the integral of the posterior probability distribution function is often not an-
alytically tractable. Inverse cumulative distribution function, importance sampling, and
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rejection sampling algorithm, etc, are some sample methods to address the issue. They re-
fer mostly to unidimensional distributions and cannot be used to obtain samples from any
posterior distribution of interest and the samples are independent. The techniques based on
Markov chain overcome such problems because of flexibility and generality.
MCMC is basically Monte Carlo integration using Markov chains. It is required to in-
tegrate over possibly high-dimensional posterior probability distributions to make an infer-
ence about the parameters given the data. It samples from posterior distribution by Markov
chain and computes the mean. MCMC methods are based on construction of Markov Chain
(MC) that converges to the posterior distribution of the parameter of interest. The MCMC
output is a dependent sample since in every step they produce values depending on the pre-
vious one as it is generated from Markov chain. The iterative procedure can be described
in the following way:
A Markov Chain is a stochastic process {α(1), α(2), α(3), ..., α(T )} such that
f(α(t+1)|α(t), α(t−1), ..., α(1)) = f(α(t+1)|α(t)). The distribution of α at sequence t + 1
given all of its previous α values depends only on the value αt of previous sequence t.
Also, f(α(t+1)|α(t)) is independent on time t. As t→∞ the distribution of α(t) converges
to its equilibrium distribution and that is independent of the initial values of the chain α(0).
Construction of a Markov chain is essential to generate a sample from f(α|y) with two
desired properties:
• f(α(t+1)|α(t)) should be easy to generate.
• Equilibrium distribution of the selected Markov chain must be the posterior distribution
of interest f(α|y).
We then follow these steps after constructing Markov chain:
1. Select an initial value for α(0)
2. Generate samples until the equilibrium distribution is reached.
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3. Monitor the convergence of the algorithm with convergence diagnostics. We generate
more samples from the target distribution upon failure.
4. Cut off some initial “B” observations as burn in period.
5. Consider {α(B+1), α(B+2), ..., α(T )} samples after the burn in period as the sample for
the posterior distribution.
6. Plot and obtain the summaries of the posterior distribution.
Gibbs Sampling and Metropolis Hasting are the two most popular MCMC methods used
by researchers to estimate the corresponding posterior distributions with accuracy. We will
discuss briefly the Gibbs sampling, the method we used in our study.
1.3.1 Gibbs Sampling Algorithm
The Gibbs sampler was introduced by Geman and Geman in 1984. It is a MCMC algorithm
used to obtained a sequence of samples from the posterior distribution of the parameters
when the direct sampling methods are difficult to perform. This is a special case of single-
component Metropolis-Hasting algorithm using as proposal density, the full conditional
posterior distribution. Gibbs sampling algorithm can be summarized in the following steps:
1. Set initial value for α(0).
2. For t = 1, 2, 3, ..., T repeat the following three steps.
(a) Set α = α(t−1).
(b) For j = 1, 2, 3, ..., D, update αj from αj ∼ f(αj|α1, α2, ..., αd−1, αd+1, ...αD, y).
(c) Set α(t) = α and save it as the generated set of values at (t + 1) iteration of the
algorithm.
For a given particular state of chain α(t), we generate the new parameters values by αt1
from f(α1|αt−12 , αt−13 , ..., αt−1J , y)
5
αt2 from f(α2|αt−11 , αt−13 , ..., αt−1J , y)
...
αtj from f(αj|αt−11 , αt−13 , ..., αt−1j−1, αt−1j+1, ..., αt−1J , y)
...
αtJ from f(αJ |αt−11 , αt−12 , ..., αt−1J−1, y)
Generating values from f(αj|α1, α2, ..., αj−1, αj+1, ..., αJ , y) is relatively easy as it is a uni-
variate distribution and can be written as f(αj|α1, α2, ..., αd−1, αd+1, ...αD, y) ∝ f(α|y),
keeping the rest of variables constant except αj .
1.4 Histogram Smoothing Prior
The statistical technique used to reduce or eliminate short-term irregularities and extract
real trends and patterns from data results is smoothing. It reduces the variance and improves
the accuracy of estimates. Different smoothing methods are applied depending on the
type of data and purpose of the study, for instance, random walk, moving average, simple
exponential, linear exponential, and seasonal exponential smoothing, etc. Many smoothing
methods involve a series of observations y1, y2, ..., yn at equally spaced observations.
We have considered a histogram smoothing prior which is applicable to frequency plots,
including those deriving from original data with equally spaced intervals. We assumed that
continuous variable data are grouped into frequency counts with fq being the observation
between points tq−1 and tq. It is thought that g(x) possesses a continuous first derivative for
all points on that interval to follow some similar property of smoothness. We treat the bins
of histogram under the assumption that they are related in a certain manner. The limitation
of histogram smoothing is that its estimate for g(x) can be discontinuous at several points
in an interval where it does not satisfy the smoothness property. Our concern is to overcome
with independent observations whose common distribution is not limited to any particular
family of distribution in Bayesian approach.
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We have considered independent and identically distributed (i.i.d.) with unknown den-
sity which is concentrated on a finite interval of real line. Let piq be the probability density
that an observation is in the qth interval and g(x) be an underlying density of smoothness:
piq =
∫ tq
tq−1
g(x)dx
Since observations are mutually independent, the observed deaths (fq) are assumed to be
multinomial with parameters {pi1, pi2, ..., piQ} satisfying
∑
piq = 1, and index n =
∑
fq.
We express piq through a multiple logit model given by
piq = exp(φq)/
∑
k
exp(φk) (1.2)
φk are considered to be multivariate normal distribution with means {m1,m2, ...,mQ} and
Q×Q covariance matrix “V”. We have assumed prior on pi′qs: piq = pq/
∑
k pk or
mq = log(pq/
∑
k
pk) (1.3)
where pq is population at risk at qth interval. Covariance matrix (V) is assumed to be a
first order dependence between neighboring frequencies on the histogram with common
variance σ2 and correlation ρ. Therefore,
Vij = ρ
|i−j|σ2 (1.4)
where (i = 1, 2, ..., Q; j = 1, 2, ..., Q), σ > 0, and ρ > 0. In detail, the elements of
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covariance matrix V are given by:
V =

σ2 σ2ρ σ2ρ2 · · · σ2ρn−1
σ2ρ σ2 σ2ρ · · · σ2ρn−2
σ2ρ2 σ2ρ σ2 · · · σ2ρn−3
...
...
... . . .
...
σ2ρn−1 σ2ρn−2 σ2ρn−3 · · · σ2

(1.5)
The elements of the matrix V take variance to be σ2 and the correlation between adjacent
bins of the histogram to be ρ|i−j|. This correlation tends to zero as |i − j| is large and to
|ρ| as |i − j| tends to unity. We observe that |i − j| a unity for consecutive bins for the
histogram. Hence, for i 6=j and ρ > 0, bins are most closely related when |i− j| = 1, and
become less closely related as |i − j| gets larger than 1. These assumptions utilize prior
beliefs about the smoothness of the histogram of the data. The elements of the matrix V −1
are given by
V −1 =

1
σ2(1−ρ2) − ρσ2(1−ρ2) 0 · · · 0
− ρ
σ2(1−ρ2)
1+ρ2
σ2(1−ρ2) − ρσ2(1−ρ2) · · · 0
0 − ρ
σ2(1−ρ2)
1+ρ2
σ2(1−ρ2) · · · 0
...
...
... . . .
...
0 0 0 · · · 1
σ2(1−ρ2)

(1.6)
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Chapter 2
Bayesian Age-Period-Cohort Model of Lung Cancer Mortality
2.1 Introduction
Lung cancer (LC) is the leading cause of cancer deaths in the US, where cancer remains the
second most common cause of deaths [2]. In 2011, 14% of all cancer diagnoses and 27%
of all cancer deaths were due to LC. More people in the United States die from LC than any
other type of cancers which is true for both men and women. After increasing for decades,
LC rates are decreasing nationally as fewer people smoke cigarettes [7]. However, it is still
one of the biggest threats for public health. About 221,200 new cases and an estimated
158,040 deaths were reported in the American Cancer Society‘s estimates for LC in the
United States for 2015. It is of strong public interest to study the trend, number of LC
deaths, and the corresponding mortality rates for public health.
Age-period-cohort (APC) modeling has been a well-known issue in epidemiology [8–
14]. The non-identifiability problem for parameters estimation has been drawing the atten-
tion of many researchers. It exists because of linear relationship of age, period, and cohort.
To resolve this problem, several approaches have been suggested by researchers to analyze
the trend in cancer epidemiology [12, 15–17]. This study applied Holford approach [12] to
analyze the effects.
In this study, we analyze LC mortality of the USA based on age at death, period at
death, and birth-cohort through Bayesian APC model with histogram smoothing priors.
The Bayesian method extracts the necessary information from the data to describe the
trend observed by exploring the uncertainty associated with functions of parameters. Var-
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ious studies have been carried out through Bayesian APC analysis [18–20] with different
smoothing priors. But, to the best of our knowledge, histogram smoothing prior has not
been considered in Bayesian modeling. We have assumed that the densities of APC pos-
sess similar property of smoothness to adapt histogram smoothing prior. Our hypothesis
was that the mortality rate decreases in 21st century. Hence, the reference period 1996-2000
was considered. The analysis has been executed with statistical packages R and WinBUGS.
2.2 Objective
The objective of our study is to estimate the time trend for the mortality or incidence of
a particular disease for a large population. The analysis of trends in epidemiology is an
important way of monitoring the behavior of diseases. It can be used to monitor etiology
of disease and assess the effect of public health policies in the form of prevention, improve
treatment, and cost assessment. The model can be used to forecast trends in health care
needs and effect of public health proposals for disease control. Vital statistics provide
epidemiologists with a useful first approach to understanding the significance of a disease,
and they generally provide hints on etiology. The effect of age, period, and cohort can
be analyzed through longitudinal trend. This trend provides crucial information about the
status of a particular disease whether trend is increasing, decreasing, or stationary. These
three things have different significant meaning to epidemiologists. They help to provide an
insight into the dynamics of the spread of disease in the population.
In this study, we attempt to study mortality rate and incidence due to lung cancer in the
USA based on the different age groups, period groups, and birth-cohort groups. It has been
estimated the mortality rate due to lung cancer in the USA for different age groups. We
have also estimated the relative risk due to period effect, and relative risk due to birth-
cohort over time in longitudinal trend. Since it is rare events, observed mortality counts
due to lung cancer have been assumed to follow Poisson probability distribution to apply
to generalized linear model in Bayesian modeling. To address the uncertainty and infer-
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ences with respect to parameters in Bayesian modeling, the priors are chosen from data
itself. The best model has been chosen based on the Deviance Information Criterion (DIC).
To overcome inability to address the independent observation whose common distribution
is not limited to any particular distribution, we have attempted to implement histogram
smoothing prior in Bayesian modeling and analysis.
2.3 Literature Review
Longitudinal trends of incidence and mortality rates of a particular disease generally pro-
vide important information for disease etiology to epidemiologists. Age (age at death), date
at death (period), and date of birth (birth-cohort) are three time factors commonly consid-
ered for investigation to a disease. Different combinations of these three factors have been
a great concern to investigators for the study. The effect of time in terms of longitudinal
response could be an important implication from various perspectives. Age plays an impor-
tant role in the risk of most of the diseases, so that it is included in almost any analysis of
disease incidence and mortality. Date of birth or birth-cohort also can be another important
temporal factor in disease incidence because a particular level of exposure may be clustered
by generation. This factor can be identified by the date of enrollment in the study. All three
temporal effects - age, period, and cohort - are thought to be useful by epidemiologists.
The literature is very rich with respect to estimation of parameter in age period cohort
model. D. Clayton and E. Schifflers proposed the age cohort and age period model in
1987 while modeling for temporal variation in cancer rates I [8]. They analyzed Bladder
cancer incidence in the region of Birmingham based on age cohort and age period model.
While doing so they noticed that these factors together could provide epidemiologists more
insight about any disease. Hence they proposed age period cohort model in 1987 [10] con-
sidering all three factors together to analyze breast cancer mortality in Japan with special
reference to the phenomenon of Clemmesen’s hook. D. Clayton in 1987 handled this sit-
uation through drift model approach. They faced un identifiability property for estimating
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parameter for the model because of linear relationship among them. Theodore R. Hol-
ford, in 1983, suggested to address this issue through estimable function [21]. In 1992, he
again came up with various approaches to address non identifiability property in parameter
estimation. He has suggested estimable contrasts of parameter, design matrix for linear
and curvature partition, interaction with non temporal variables, interaction with tempo-
ral variables, and alternative parameter constraints where he has suggested as zero slope,
equate two or more effects, and restricted range for slopes [12]. Leonhard Knorr-Held in
2001 used a generalized Bayesian age-period- cohort (APC) model to a data set to obtain
the trend [18]. Robert M. O’Brien in 2010 also has suggested different approaches with
two fundamental problems associated with estimation of parameter [22]. Ramon Cleries
(2010) applied the model through constraint parameter [20]. Irene O.L. et.al suggested
through curvature approach [19].
We have adapted Holford approach to address un-identifiability problem by introducing
a constraint while estimating parameters [12]. We have assumed the slope of period zero
at first stage to allow independent estimation of parameters. Then, we introduced the fitted
values to only period effect. The rationale to this approach is the following:
• An age effect has a strong biological association on cancer, is a well established result.
Hence we can not ignore age effect.
• Cohort had a stronger association with incidence than period, has been shown in em-
pirical results.
• Assuming slope of period is zero itself is less restrictive than ignoring the whole period
effect.
2.4 Data Source
The Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer
Institute (NCI) is an authoritative source of information on cancer incidence and survival
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in the United States [23]. It is dedicated to provide information on cancer statistics in
order to minimize cancer burden among the U.S. population. SEER Program currently
collects and publishes cancer incidence and survival data for approximately 30% of the
US population. It includes 26 percent of African Americans, 38 percent of Hispanics, 44
percent of American Indians and Alaska Natives, 50 percent of Asians, and 67 percent
of Hawaiian/Pacific Islanders. The SEER Program is the only comprehensive source of
population-based information in the United States that includes stage of cancer at the time
of diagnosis and patient survival data [24]. This program, which was established in 1973,
collects data on cancer cases through 20 different registries from various locations and
sources throughout the United States.
The SEER data are being used by many researchers, clinicians, public health officials,
legislators, policymakers, community groups, and the public. It is updated annually and
provided as a public service in print and electronic formats. The data on patient demo-
graphics, primary tumor site, tumor morphology and stage at diagnosis, first course of
treatment, and follow-up for vital status are routinely collected by the SEER program. The
SEER reports mortality data and it can be obtained from National Center of Health Statis-
tics. The population data used in calculating the cancer rates is obtained periodically from
Census Bureau [25]. The SEER based data has been improved through web-based access
to the data and analytic tools and connected to other national data sources. A statistical
software named ‘SEERStat‘ is being used to extract the data from database.
2.5 Statistical Analysis
The data contains incidence and corresponding mortality due to lung cancer (LC) in the
USA from 1971 to 2010, the most recent available data in the database. In our study, we
have considered age at death due to lung cancer as “age”, period at death due to lung cancer
as “period”, and date of birth of the person as “cohort”. For statistical analysis, we have
aggregated incidence and mortality into thirteen 5-year age groups (20-24 years to 80-84
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years). Age groups are 22, 27, 32, ..., 72, 77, 82 years. There are eight 5-year periods
(1971-1975 years to 2006-2010 years) and are 1973, 1978, ..., 2003, 2008.
We have considered these age groups (22-82 years) in our study because SEERStat does
not give the counts for less than 10 numbers of observations and we have many such cases
particularly below the age of 20 years and above 84 years for mortality counts. Also,
cigarette smoking is the most common cause of LC and this habit is likely to develop in
adult ages. Ages, periods, and cohorts are represented by their medians during our study.
These age groups and calendar periods involved 20 (13 age groups+8 periods -1) possibly
overlapping 5-year cohorts [8, 10]. Total number of birth-cohort has been computed as
follows: K = I + J − 1 (I =Age groups, J =period groups). A person died due to lung
cancer in 1973 and he/she could have been 82 years old. So, he/she could be in birth-cohort
1891. Similarly, if a person died with lung cancer in 2008 and he/she was 22 years old, the
possible birth-cohort could be 1986. Hence, if we divide time between 1891 to 2008 into
5-year group, we have ended up to 20 possible birth-cohorts given by 1891, 1896, 1901, ...,
1976, 1981, 1986.
Table 1: Number of Ages and Periods Used to Compute Possible Birth-Cohorts
Periods
Ages 1973 1978 1983 1988 1993 1998 2003 2008
22
27
.
.
.
.
82
The following relation; k = I + j − i, is useful to calculate required ages, periods, and
birth-cohorts. Where (k =Cohorts, I =Age groups, j =periods, i =ages). Ages, peri-
ods, and birth-cohorts calculated are used for statistical analysis. In this manner, we have
computed and arranged the available data into five different columns named age, period,
14
Table 2: Calculated Ages, Periods, and Corresponding Cohorts
k I j i
13 13 1 1
14 13 2 1
...
...
...
...
20 13 8 1
12 13 1 2
13 13 2 2
...
...
...
...
19 13 8 2
...
...
...
...
1 13 1 13
2 13 2 13
...
...
...
...
8 13 8 13
cohort, mortality and corresponding incidence due to lung cancer and we perform basic
preliminary statistical analysis.
Age specific LC mortality rates seem stable for age groups 40 years and lower. Within
every period, it can be noticed that mortality rate is increasing until age groups, 77 years
and decreasing afterwards, Figure 1. Age specific mortality rates are lower for lower age
in all birth cohorts. In similar fashion, it is significantly high for older birth cohorts. Older
people of all birth-cohorts might be at high risk of ending up as lung cancer patients as
shown by Figure 2. Period specific mortality rates for lung cancer are lower for lower age
groups for every period. The greater the age, the more mortality rates seem to be for each
period. The mortality rate for age group 82 years was lower than age groups 67, 72, and 77
in early periods. However, it seems to be greater in 1993 and recent periods, Figure 3.
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Figure 1.: Age-Specific Lung Cancer Mortality Rates per 100,000 in the USA by 5-Year
Period
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Figure 2.: Period-Specific Lung Cancer Mortality Rates per 100,000 in the USA by 5-Year
Age Group
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Figure 3.: Age-Specific Lung Cancer Mortality Rates per 100,000 in the USA by 5-Year
Birth-Cohort
Cohort specific mortality rates due to lung cancer are higher for age groups in early
birth-cohorts. However, it seems to be decreasing for lower age groups for recent birth-
cohorts. We have noticed that older people are at more risk of dying due to lung cancer
than younger people throughout the birth-cohorts. Within the same age group, the mortality
rate of younger birth-cohort is relatively lower than older birth-cohort, as shown by Figure
4 [21].
We have plotted mortality rates as an initial exploration whether rates are proportional
between periods or cohorts. These plots might help to have preliminary idea that model
possibly includes as contributing factors. Log scale rate plots of Figure 1 and Figure 2 will
exhibit almost parallel lines if age specific rates are proportional between periods which
might indicate age-period model. Similarly, log scale rate plots of Figure 3 and Figure
4 will exhibit parallel lines if age specific rates are proportional between cohorts, which
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Figure 4.: Cohort-Specific Lung Cancer Mortality Rates per 100,000 in the USA by 5-Year
Age Group
possibly indicates age-cohort model [26].
2.6 Modeling Lung Cancer Mortality
dij and nij are observed number of deaths for age group i and period j and total number of
person-year at risk respectively. It has been assumed that dij ∼ Poisson(λijnij)
log(λij) = log(nij) + αi + βj + γk (2.1)
αi is age effect (i = 1, 2, . . . , I), βj is period effect (j = 1, 2, . . . , J), and γk is cohort
effect (k = 1, 2, . . . , K) where K = I + J − 1 and k = I + j − i.
The choice of prior is always an important issue in Bayesian Statistical Analysis. Nor-
mality is a common assumption for time effect-specific (age, period, and cohort) smoothing
prior formulations in most of the smoothing approaches including power link model [27].
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Our assumptions regarding age, period, and cohort are not restricted to any particular fam-
ily of distributions. Histogram smoothing is a technique for the analysis of independent and
identically distributed (i.i.d.) observations with unknown density which is concentrated on
a finite interval of the real line [28]. A histogram helps to visualize the data since it adapts
replacing a large point set with a compact approximation of the underlying distribution. It
eliminates the random fluctuation that usually occurs with estimate of parameters and pre-
vents instability in the situation where there are very few counts of deaths as in the younger
age groups in our study. The variance parameters (age, period, and cohort variances) pro-
vide information about degree of smoothness. The larger the values, the greater the degree
of smoothing [29]. The trends corresponding to age, period, and cohort were smoothed
using histogram smoothing prior. That being said, it is crucial to notice that the model did
not appear to be sensitive to the prior of variance (roughness) parameters.
The relation, cohort = period − age, leads to a non-identifiability problem where a
constraint should be introduced [21, 30]. We have adopted Holford approach to represent
the effects [11, 12]. It is observed that age-cohort model with an unstructured error term is
enough to describe the extra Poisson variation [31]. Hence, we estimated age and cohort
effects assuming slope of period is zero considering 11th (1941) cohort as reference. Then,
the fitted values are introduced to a model that includes only period effects considering 6th
(1998) period as reference. In this way, we can obtain independent effects of age, period,
and cohort. A similar approach with respect to choice of effect has been previously adopted
[19, 20]. The parameter estimates for the model are obtained from posterior distribution.
Median is the point estimate. The model goodness-of-fit was measured by the posterior
mean deviance D¯ [32]. The deviance information criterion (DIC) has been considered to
compare the models which adjusts the posterior mean deviance for the number of parame-
ters in the model [32]. A smaller DIC indicates the better fit. 95% credible intervals were
obtained using 2.5th and 97.5th percentiles of the Monte Carlo Markov Chain run.
We fitted partial as well as full models and compared the different models based on DICs
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obtained. We investigated age, period, and birth-cohort models with their different possible
interactions. However, we observed no evidence of significance interactions as indicated
by DICs. The full model, which contains age at death, period at death, and birth-cohort,
shows best fit with lowest DIC in comparison of partial models Table 3.
Table 3: DIC Values for Different Combinations for Age, Period, and Cohort Models for
Deaths Due to Lung Cancer in the USA
Model DIC
age 165722
period 1,923,440,000
cohort 1,041,650,000
age, period 116,025
period, cohort 233,250,000
period, cohort, period*cohort 850,328,000
age, period, age*period 120,595
age, period, cohort, age*period 11924
age, cohort, age*cohort 8,021.3
age, cohort 7171.17
age, period, cohort 2119.65
2.7 Result
We observed that it is stable around 1 or 2 deaths per 100,000 for age groups 32 and below
and is around 5 deaths for age group 37, Figure 5, on average annually. However, it had
an upward inflection with age groups 42 and above. It is consistent with higher age which
is also observed in preliminary analysis as shown in Figure 1. We have observed that it
reaches the peak of 325 (95% CI: 323-326) deaths annually per 100,000 for the age group
82 years. The 95% point wise credible intervals are the intervals of the mean function
which looks narrower in our model. This might be due to the scale of model which is
substantially broader and has greater variability.
We have witnessed a continuous increase in the relative risk in period effects peaking in
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Figure 5.: Estimated Age-Specific Annual Mortality Rates (Age Effects) in 5-Year Age
Group
period 1993 and then downward inflection afterwards, Figure 6, consistent with Figure 2.
It indicates that risk of LC mortality rate is improving after this calendar period. The
result is well underlined by research [33]. We have noticed that risk of mortality rate de-
creased most rapidly in periods 2003-2008, which has been reinforced in similar research
[1, 33]. It should be noticed that risk of birth-cohort increased sharply among cohorts from
the late 1800s into the early 1900s before reaching a plateau and then declining, Figure 7.
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Figure 6.: Estimated Relative Risks for 5-Year Calendar Periods (Period Effects) with 95%
Credible Interval with Respect to Reference Period 1998
The curvature of cohort effect depicts an increase in peak risk at birth cohort 1926 and
declines continuously until 1950 as it was observed in Figure 4. The risk of LC mortality
peaked in birth-cohort 1926-1931 that is supported by similar research [33–35]. We have
observed an increase in birth-cohort slope in 1950, indicating a deteriorating of birth-cohort
trend in LC mortality after 1950. The results have strongly agreed in similar research [33].
It can be seen in a slowing of decline in risk after cohort 1950 in almost all age intervals,
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Figure 7.: Estimated Relative Risks for 5-Year Birth Cohorts (Cohort Effects) with 95%
Credible Interval with Respect to Reference Cohort 1941
which indicates that the worsening birth-cohort risk is not an artifact of the model fitting,
Figure 4. We have noticed declining birth-cohort risk after 1960. The relative risk due to
LC mortality by birth-cohort reflects upward inflection for people born around 1975 which
is consistent with mortality rates by cohort described in Figure 3. Wider 95% credible
interval was observed in the latest cohorts because of fewer LC death points leading to
greater uncertainty. The estimated parameter values of age, relative risks of period, and
cohort components with their 95% credible intervals are described in Table 4.
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Table 4: The Posterior Summaries of Parameters for Lung Cancer
node mean sd MC error 2.50% median 97.50%
α1 -13.32 0.02952 2.53E-04 -13.38 -13.32 -13.27
α2 -12.36 0.01746 1.59E-04 -12.4 -12.36 -12.33
α3 -11.12 0.009049 9.68E-05 -11.14 -11.12 -11.11
α4 -9.92 0.005063 8.18E-05 -9.93 -9.92 -9.911
α5 -8.922 0.003286 7.88E-05 -8.928 -8.922 -8.915
α6 -8.113 0.002531 8.22E-05 -8.118 -8.113 -8.108
α7 -7.471 0.002214 8.72E-05 -7.475 -7.471 -7.468
α8 -6.946 0.002105 9.17E-05 -6.95 -6.946 -6.943
α9 -6.514 0.002113 9.72E-05 -6.518 -6.514 -6.511
α10 -6.182 0.00214 1.02E-04 -6.185 -6.182 -6.179
α11 -5.935 0.002463 1.20E-04 -5.938 -5.935 -5.932
α12 -5.792 0.00257 1.25E-04 -5.796 -5.792 -5.788
α13 -5.732 0.002731 1.29E-04 -5.736 -5.732 -5.728
β1 -0.06153 0.001943 2.95E-05 -0.06532 -0.06151 -0.05774
β2 -0.02363 0.001686 2.30E-05 -0.02695 -0.02362 -0.02035
β3 0.009501 0.001491 1.58E-05 0.006575 0.009505 0.01241
β4 0.04091 0.001349 9.89E-06 0.03826 0.04092 0.04355
β5 0.04269 0.001285 8.66E-06 0.04018 0.04269 0.04521
β6 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000
β7 -0.00972 0.001353 2.39E-05 -0.01232 -0.00973 -0.007082
β8 -0.03982 0.001489 3.46E-05 -0.04259 -0.03985 -0.03696
γ1 -0.6358 0.005803 1.50E-04 -0.6465 -0.6359 -0.6247
γ2 -0.4373 0.003925 1.41E-04 -0.4439 -0.4374 -0.4303
γ3 -0.2734 0.003309 1.38E-04 -0.2786 -0.2734 -0.268
γ4 -0.1228 0.002905 1.29E-04 -0.1271 -0.1229 -0.1182
γ5 0.01356 0.002659 1.22E-04 0.009697 0.01341 0.01745
γ6 0.1092 0.002518 1.19E-04 0.1056 0.109 0.1129
γ7 0.1639 0.002406 1.15E-04 0.1605 0.1638 0.1674
γ8 0.2139 0.002306 1.10E-04 0.2106 0.2137 0.2172
γ9 0.1904 0.002225 1.03E-04 0.1873 0.1903 0.1936
γ10 0.111 0.002207 9.68E-05 0.1077 0.1109 0.1144
γ11 0.0000 0.00000 0.00000 0.0000 0.0000 0.0000
γ12 -0.1799 0.002305 8.37E-05 -0.1838 -0.1799 -0.1758
γ13 -0.3449 0.002637 8.19E-05 -0.3496 -0.345 -0.340
γ14 -0.3739 0.003178 7.87E-05 -0.3798 -0.374 -0.3678
γ15 -0.4515 0.004365 7.68E-05 -0.4599 -0.4515 -0.4429
γ16 -0.7276 0.007546 8.76E-05 -0.7425 -0.7276 -0.7127
γ17 -0.9779 0.01449 1.36E-04 -1.006 -0.9778 -0.9495
γ18 -0.911 0.02636 2.25E-04 -0.9635 -0.9107 -0.8602
γ19 -0.7505 0.04461 3.55E-04 -0.8389 -0.7499 -0.6639
γ20 -0.6082 0.07892 6.07E-04 -0.7648 -0.6073 -0.4561
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Box plots 8, 9, and 10 have slightly different box plots from the traditional box plots.
The middle bar represents the posterior mean of the parameter, while limits of each box
represent posterior quartiles. The ending whisker lines represent the 2.5% and 97.5% pos-
terior percentiles respectively. They provide Bayesian confidence interval called credible
interval which give interval estimation of parameter of interest.
Figure 8.: Box Plot of Estimated Parameters for Age Group
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Figure 9.: Box Plot of Estimated Parameters for Relative Risk of Period
Figure 10.: Box Plot of Estimated Parameters for Relative Risk of Cohort
2.8 Model Validation
The inferences of a Bayesian analysis are conditional on the appropriateness of an assumed
probability model. It is essential to be satisfied that our assumptions are a reasonable26
approximation to reality, though it is not generally believed any model is actually true.
Various aspects of an assumed model might be questioned: observations that do not fit, the
distributional assumptions, link functions, which covariates to include, and so on.
We have analyzed the residual to check the robustness and fit of the model. To examine
the standard errors with their 95% credible intervals for fitting of each observation and the
identification of possible outliers, we have considered posterior simulation. The standard-
ized residuals are obtained to measure the deviation between observations and estimated
expected values, and should ideally be assessed on data that has not been used to fit the
model. It is obtained by taking deviations of the data to their expectations for all obser-
vations based on posterior simulations and dividing by their standard deviations. We have
used Pearson residual given by:
residuali(θ) =
yi − E(yi|θ)√
var(yi|θ)
(2.2)
It is a function of θ (parameter) and therefore has a posterior distribution. If it is considered
as a function of random yi for fixed θ, it has mean 0 and variance 1 and so we might broadly
expect values between -2 and 2 for adequate model. Standardized errors with 95% credible
intervals are given in Figure 11.
Almost all of the standardized residuals with their bands are randomly distributed around
zero within the range of -2 to 2, a clear indication of a well fitted developed model to the
data.
2.9 Conclusion
We observed that there is strong evidence of significant changes in risk from LC by birth
cohorts. Initial increasing risk of mortality trend is observed in the early 19th century.
There could be many possible etiologic factors like increased air pollution by gases and
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Figure 11.: Standardized Residual Plot
dusts caused by industries, the asphalting of roads, the increase in automobile traffic, ex-
posure to gas in World War I, the influenza pandemic of 1918, working with benzene or
gasoline [36, 37]. Although LC can be caused by environmental exposures as well, 80-
90% of LCs are attributed to cigarette smoking and secondhand smoke [1]. Tobacco use
has been identified as the most contributing risk factor for LC in developed countries and is
approaching to be first in developing countries [38]. The peak of birth-cohort risk occurred
in 1926, which may be caused by the earlier use of cigarettes [35, 39, 40]. These cohorts
had the highest prevalence of cigarette smoking during World War II [40]. Over half of the
young population used to smoke cigarettes. Mortality rate is observed to be higher for age
groups 60 years and above. People born around 1926 had reached 60 years and above after
1980, where the higher risk has been observed in period effect. The risk of LC grew with
increasing age which might be due to the lifetime number of cigarettes increasing with age
as the risk can be interpreted as a reflection of past smoking [41–43].
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There has been no significant breakthrough in lung cancer treatment that explains the
decrease in mortality rates after calendar period 1993 [44]. However, we have witnessed
the decrease in slopes of incidence rate curves after 1993. It might suggest that the decrease
in mortality rates is because of a decrease in risk of LC instead of an improvement in
survival. The impact on initiation stage of decrease in tobacco carcinogen exposure and
increase in smoking cessation beginning around 1960 might have caused the substantial
decline in calendar-period risk after 1993. Because of lower risk in mortality from period
1993, decreasing slope of risk to birth-cohort 1961-1971 might have been observed. A
reduction in risk of death in the USA due to LC is observed through periods 1991-2010
from period-specific trend. Older people are relatively at more risk than younger ones. A
similar conclusion has been discussed in the study [2].
A decreasing mortality trend was observed during cohorts 1926-1951 due to prevalence
of smoking filter cigarettes and low-tar cigarettes [35]. The risk of death due to LC was
slightly increasing in 1951-1961 possibly because of the promotion of deeper inhalation
of smoke [37]. It may reflect a failure of widespread tobacco control efforts by private
and public health agencies in the 1960s [38] to break through social and cultural aspects
which influenced teenage-smoking [45, 46]. Marijuana contains the same carcinogen as is
found in cigarettes [47]. It is possible that increased smoking of marijuana by teenagers and
young adults in the 1960s and in the 1970s contributed to an increase in risk of birth-cohort
around 1950.
Since 1964 when the first Surgeon General’s report on the health consequences of smok-
ing was published, cigarette smoking cessation rates increased and cigarette smoking ini-
tiation rates decreased more rapidly among men than women [37]. The increased use of
cigarettes and marijuana since 1991 among teenagers might likely be reflected by an in-
crease in birth-cohort risk for people born around 1975. Increased smoking from 1971
possibly increased the relative risk of death from LC in birth-cohort around 1980 and con-
temporary cohorts [37]. People born during 1880-90 had a relatively high prevalence of
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cigarette smoking with mixed tobacco and tar that could have led to an increase in risk.
However, insufficient data earlier than period 1971 prevented precise estimation of risk
trend among older periods.
Our study is concentrated in well-defined population of the USA. The proposed model
fits mortality data well in general. Hence, it is reasonable to argue that our approach ex-
tracts the necessary information from the data to explain the possible trend. The Bayesian
approach can be adapted to incidence and mortality data. Of course, it can provide further
information on potential benefits of analyzing LC mortality.
2.9.1 Contribution
In this chapter, we have studied lung cancer mortality rate in the USA through Bayesian
analysis with histogram smoothing prior suggested by T. Leonard [28]. It is noted that we
have discovered several advantages using Bayesian approach and with histogram smooth-
ing prior. We would like to list some of the important contributions as a result of the current
study.
1. We have implemented histogram smoothing prior in Bayesian modeling to model mor-
tality data and can be implemented to identify mortality rate and corresponding inci-
dence in different cancer and other related fields.
2. We have implemented Bayesian approach in addressing independent observations whose
distribution is not limited to any particular family of probability distributions. We have
assumed independently and identically distributed (i.i.d.) observations with unknown
mortality density which is concentrated on a finite interval of real line.
3. The developed statistical model includes counts of death for each age group, period,
and birth-cohort and estimates the effect of LC as function of time.
4. The developed statistical model can be easily extended for further improvement for
estimation of parameters with proper approach of breaking the component of precision
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matrix.
5. We have identified mortality rates based on different age groups, relative risks due to
period effect and relative risk due to birth-cohort effect in lung cancer in the USA.
6. The proposed statistical model can be used to predict future age specific mortality rates
due to lung cancer and relative risks due to period and birth-cohort.
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Chapter 3
A Parametric Analysis of Serum Cholesterol Levels by Gender and Race
3.1 Introduction
Cigarette smoking, high blood pressure, and high blood cholesterol are the most clearly
established risk factors that have been identified as being strongly associated with coronary
heart disease (CHD) [48]. Total serum cholesterol level (SCL) is a major risk factor for
CHD which is the leading cause of death in the United States [49–51]. CHD is responsible
for more deaths than all forms of cancer combined [48]. A recommendation has been made
that total SCL for adults should be below 200mg/dl and individuals with values between
200mg/dl to 239 mg/dl should be considered as borderline high risk; those with values
more than 240 mg/dl should be regarded as high risk for CHD [48–52]. Hence, a detailed
study of SCL is essential for public health.
A better understanding of lipoprotein production and removal, lipoprotein receptors, and
apolipoprotein is needed because they are considered the most important factors in choles-
terol. Various studies have been carefully executed to reduce SCL through different means
through diets and drugs [53, 54]. Significant positive changes have been achieved through
dietary means as well as through drugs in reducing cholesterol levels in test subjects. Rele-
vant of effects of drugs on SCL can be carefully handled through drugs that have previously
been recognized. Studies have been carried out in order to address these issues as well [55–
57]. Attempts have been made to make prediction about the SCL based on age in order to
better understand the relationship between age and cholesterol levels [58–60].
Precisely defined diets and pharmacologic interventions to reduce blood cholesterol and
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other lipids are presently being studied in individuals under carefully controlled condi-
tions to investigate effects of drugs on SCL [61]. The compounds that are more effective,
economical, and safe for people in the reduction of blood cholesterol are under intensive
research. Longevity of life in the elderly population who have a high-density lipoprotein
cholesterol has also been investigated in order to better understand its effects on survival.
That being said, there are very few studies that have been carried out addressing SCL,
based on gender and race. SCL is heavily dependent on two factors: it is strongly influenced
by food intake of an individual and it varies by race. In addition, the resistance to disease
capabilities varies by gender and race as well. It is therefore equally important for the study
of SCL to take both factors into consideration.
In this chapter, we performed parametric analysis of the SCL and statistically discuss
the behavior based on gender and race. We identified the probability distributions that best
describe the cholesterol level for different genders and races. Such a characterization will
be crucial in obtaining central tendency, dispersion, skewness, and kurtosis of distributions.
Although it would be helpful to speculate on the effect of cholesterol level on race and
gender, our study will be able to provide further insight through parametric analysis into
its nature and will assist in exploring SCL’s various aspects. Succinctly stated, the purpose
of this study is to enable researchers to identify subgroups of the population who are at
risk with respect to SCL and to identify distributional differences among the population
subgroups of epidemiological interest.
3.2 Objective
The purpose is to study, parametrically, the cholesterol level of individuals based on gender
and race and to determine the probability distributions that the cholesterol level resembles.
The study concludes that the cholesterol level for different genders and races exhibits sig-
nificant racial and gender differences in terms of probability distributions. Vital statistics
obtained from identified probability distributions could be useful information. We intend
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to obtain skewness and kurtosis based on gender and ethnicity of average cholesterol level.
A recommendation of any kind of means for an individual, such as diets or drugs, might
differ from individual to individual, even though the individuals have the same cholesterol
level. Our study will further widen inside the behavior of cholesterol on the individuals.
It should also be taken into consideration that high level risk and borderline risk levels of
cholesterol might also be different for races and genders.
3.3 Data Source
The data utilized in this paper were made available by the inter-university Consortium for
Political and Social Research and the data for National Health and Nutrition Examination
Survey (NHANS) II, 1976-1980: Serum Cholesterol was originally collected by United
States Department of Health and Human Services.
NHANS II was conducted on a nationwide probability sample with approximately 28,000
persons. The target population for the survey was the civilian non-institutionalized popu-
lation of the United States (including Alaska and Hawaii). The NHANES II serum choles-
terol data files contain two parts of the extensive data available. One part consists of the
demographic information obtained from household interview and the other part is labora-
tory results. The survey started in February 1976 and was completed in February 1980.
Samples were selected so that certain population groups thought to be at high risk of mal-
nutrition (person with low incomes, preschool children, and the elderly) were oversampled.
Adjusted sampling weights were then conducted for persons over the age of 76, sex, and
race categories in order to inflate the sample in such a manner as to closely reflect the
estimated civilian non-institutionalized U.S. population.
In addition to the general examination components, several more detailed examinations
were performed on subsamples of the population. Our study included 11,864 persons
for SCL cases with 9,602 males and 2,262 females. The information relating to SCL in
NHANS II survey considered codes 355-357. Primary site codes were 1 and 2 for males
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and females respectively. Similarly, codes for white, black, and other were 1, 2, and 3
respectively. Male data included 8,536 white, 881 black, and 185 other individuals. On
the other hand, female data included 1,769 white, 456 black, and 37 other individuals.
Descriptive information for the total number of individuals by sex and race is presented
in schematic diagram, Figure (12) which explains how the study was systematically orga-
nized.
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Other
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Figure 12.: Schematic Diagram of Total Number of Individuals by Sex and Race
3.4 Statistical Analysis
In order to perform parametric analysis of cholesterol levels, the probability distributions
that best fit the cholesterol data are lognormal and gamma distribution. The probability
distributions were confirmed, taking into consideration all available data. Kolmogorov
Smirnov goodness of fit test was performed to identify the underlying distributions.
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The probability density function of three-parameter lognormal distribution is given by:
h(x) =

1
(x−γ)σ√2pi exp(−
[ln(x−γ)−µ]2
2σ2
), γ < x <∞, σ > 0,−∞ < µ <∞
0, elsewhere
(3.1)
The probability density function of two-parameter lognormal distribution is given by:
f(x) =

1
xσ
√
2pi
exp(− [ln(x)−µ]2
2σ2
), x > 0, σ > 0,−∞ < µ <∞
0, elsewhere
(3.2)
The probability density of Gamma distribution is given by:
g(x) =

1
Γγβγ
xγ−1 exp(−x
β
), x, γ, β > 0
0, elsewhere
(3.3)
Γγ =
∫ ∞
0
xγ−1 exp (−x)dx, γ > 0 (3.4)
where Γγ is gamma function. With respect to the lognormal distributions, µ and σ respec-
tively are mean (scale parameter), standard deviation (shape parameter), and γ a location
parameter shown in equation (3.1) and (3.2), which characterize the cholesterol levels of
most of the male cases. Gamma probability distribution represents cholesterol levels of
mostly female cases, which is shown in equation (3.3).
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3.5 Result
In this section, cholesterol level by sex and race was investigated. Distinctively different
cholesterol levels may have important implications. Being aware of the complexity of the
data, all pairwise comparisons were performed non-parametrically, not relying on any par-
ticular distribution. The mean cholesterol levels of males and females for overall behaviors
were investigated. The study performed the Mann-Whitney-Wilcoxon non parametric test
in order to identify whether or not the males and females were two identical population,
with respect to cholesterol levels.
We were able to reject the null hypothesis that male and female cholesterol levels were
coming from two identical populations (p-value=4.8e-09). It was therefore, crucial to inves-
tigate male and female, independently. We also examined the equality of mean cholesterol
levels for white, black, and other in each of the cases for males and females, to understand
if they were coming from identical populations. All comparisons were made using the
non-parametric Kruskal-Wallis test. In each of the cases, we were able to reject the null
hypothesis with a p-value=0.01289 for males and a p-value=0.006276 for females and con-
cluded that the cholesterol levels were coming from independent populations with different
means. We also tested, pairwise, a non- parametric test for white, black, and other. The
null hypothesis was rejected in each of those cases.
Table 5: The Identified Probability Distributions with the Estimated Parameters that Best
Fit the Cholesterol Level Data
Males Female
All races Lognormal(2p):µˆ = 5.35, σˆ = 0.22 Gamma: γˆ = 18.27, βˆ = 12.24
White Lognormal(3p):γˆ = −27.19, µˆ =
5.48, σˆ = 0.19
Gamma: γˆ = 12.11, βˆ = 18.60
Black Lognormal: µˆ = 5.33, σˆ = 0.24 Lognormal: µˆ = 5.35, σˆ = 0.24
Other Gamma: γˆ = 26.22, βˆ = 8.02 Burr: θˆ = 173.06, αˆ = 0.18, γˆ =
23.05
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Once the study identified racially classified populations from both males and females
that exhibit different subpopulations, the study performed the Kolmogorov goodness of fit
test to determine the underlying distribution the data follows. The study identified the over-
all male cholesterol level that exhibited lognormal probability distribution (p-value=0.06)
whereas the overall female population exhibited gamma probability distribution (p-value=0.051).
Similarly, the study identified and concluded that white males followed three parameters
lognormal probability distribution, black males followed as lognormal probability distri-
bution, and other males resembled gamma probability distribution. In addition, the study
determined that white females exhibited gamma distribution, black females exhibited log-
normal distribution, and that the other females satisfied the Burr distribution. Since the
sample size for Burr distribution was very small, the study makes a disclaimer for careful
interpretation. Estimated parameters for fitted distributions are presented in Table 5.
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Figure 13.: Age Specific Average Cholesterol Levels by Gender
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Age specific average cholesterol levels by sex were plotted to present the variability for
various ages. Cholesterol levels varied greatly in both age and sex. Mean cholesterol levels
were computed and compared statistically by gender specific averages, Figure 13. Clearly,
the average cholesterol level of an individual over 60 years of age exhibited greater variabil-
ity than those under the age of 60 and the average was consistent in both males and females.
Mean cholesterol levels were progressively and consistently higher in each succeeding age,
prior to the age of 60. This was true for both males and females. The SCL appeared to be
less volatile for ages under 60 years old and displayed a clear linearly increasing pattern
for both genders. There was no clear pattern of cholesterol levels after the age of 60 for
both genders. However, cholesterol level for females appeared to be consistently higher
than males. The study noted that above 80 years old there were relatively few data values,
as compared to other ages.
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Figure 14.: The pdf of Identified Probability Distributions that Best Fit the Cholesterol
Level Data
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The study plotted probability density functions that best described the cholesterol level
for races, for both males and females, Figure (14). There was a clear difference between
cholesterol levels of males and females. The distributions that SCL exhibited were skewed
to the right with different means and different skewness. Having known the underlying dis-
tributions, we might have a better understanding of the variability of cholesterol level and
estimates of basic statistics from which we would have been able to draw proper inferences
for different subpopulations.
Cumulative distribution function (CDF) can be used to obtain expected level of choles-
terol for genders and races and it also provides the confidence interval, Figure 15.
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Figure 15.: The CDFs of Identified Probability Distributions that Best Fit the Cholesterol
Level Data
Statistics based on distributions have been presented in Table 6. Such measurements and
analysis are common but have great implications in evaluations and treatments. Females
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Table 6: Estimated Central Tendency and Variability of Cholesterol Level Classified as
Race and Gender Using Estimated Parameters of Fitted Distributions
Mean Variance Skewness Kurtosis
Male Female Male Female Male Female Male Female
All races 216.26 223.6 2345.47 2736.34 0.65 1.24 4.25 11.46
Whites 216.71 232.25 2285.8 2728.39 0.68 -86.77 4.49 384.16
Black 212.83 217.29 2629.64 2897.67 7.2 -63.97 34.75 255.86
Other 210.26 223.8 1769.04 2567.45 0.11 0.80 2.28 2.61
appear to have a higher cholesterol level, on average, than males and the higher cholesterol
level is consistent in all the races. This finding is also applicable for variance. Significantly,
however, white individuals, both males and females, appear to have higher cholesterol
levels than other subpopulations. White females have the highest average cholesterol level
among all and have the highest kurtosis. Higher kurtosis implies more of a variance due
to infrequent extreme deviation from the mean. It was determined that white females have
the highest extreme variation from the mean cholesterol level.
3.6 Conclusion
The study identified the probability distributions for males and females that are respectively
lognormal and gamma, which were included in the study. A probability model was applied
to investigate its effect on SCL. The study will help researchers to have a greater insight
into risk factors of cholesterol levels and their behaviors. The majority of the individuals
in the data set were white and had a greater variability in both males and females. The
differences in distributions might be used as benchmarks for racial and gender comparisons,
and as possible indicators of changes in factors known to influence serum cholesterol, such
as diets and drugs.
We have witnessed that SCL increases as age increased and it is possible that SCL be-
comes more volatile as an individual becomes older, most notably when above 60 years
old, Figure 13. SCL is most likely to develop during the late teens to mid-40s [62, 63].
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Different behaviors between the race-sex groups were observed in our study. We identified
a resemblance to different probability distributions. Our findings are supported by research
[62]. The higher the level of cholesterol that an individual has, the greater the risk of subse-
quently developing CHD would be. The findings of the study were proven with prospective
studies such as the Framingham Study [64]. Since the likelihood of developing high SCL is
dependent upon race and gender, borderline high risk and high risk level of SCL are likely
to be different, according to race and gender. This observation may be subject to a further
area of research. The deeper one delves into the issues, the more useful information will be
obtained. Further information derived from future research will help researchers speculate
more precisely about SCL.
Our study suggests that the average SCL for males and females is different indicating
that to a greater extent, reliance upon the analytical precision and accuracy of laboratory
measurements will be required before making a generalized assumption about the degree
of risk of an individual. An informed decision which is based on male information cannot
be generalized to the female and vise-versa [62]. It has been clinically proven that lowering
elevated cholesterol levels will reduce the risk of CHD. The degree of risk is relative to gen-
der and race. Efforts have been made to investigate the relationship of some demographic
variables to SCL as they may relate to SCL. Our study will assist in developing guidelines
which will better inform physicians and public health practitioners of best practices, when
determining how to best treat an individual, dependent upon gender and race. The results
of this study will inform individuals and be an aid in preventing premature deaths [50].
Further, the study provides data which will aid in better understanding the relationship of
certain risk factors to the development of high SCL. The study pivots on aspects of gender
and race.
The study identified differences in probability distributions with respect to gender and
race to characterize SCL, which in turn was dependent upon diet intake. Therefore, more
careful studies of diet, eating patterns, as well as the attitudes and life style of general pop-
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ulation and specific subpopulations will help to better understand their relative relationship
to SCL. A number of retrospective case-control and cohort studies have investigated the as-
sociations between intakes of dietary fats and cholesterol and their associated risk [65, 66].
Since these habits can vary the results, based upon on race and gender, inferences made,
which do not take into account these factors, will be misleading which will most likely
have serious consequences [67].
This study has resulted in identifying the underlying distributions which now provide a
better understanding of the variability of cholesterol level and estimates of basic statistics
which include gender and racial difference in terms of probability distributions. Based
upon this information, one is able to draw proper inferences for different subpopulations.
3.6.1 Contribution
The study suggested various interesting findings that could be practically and statistically
meaningful. Vital statistics can give crucial information about the status of cholesterol
level of an individual which can lead to identifying whether an individual is at risk or not.
Statistical analysis based on gender and ethnicity also can play a major role for identifying
the associated risk due to cholesterol level. We have listed some useful notes associated
with this study.
1. The study identified the probability distributions based on gender and ethnicity that the
cholesterol level might follow. It shows that the probability distributions followed by
males and females are different which is also true with respect to ethnicity.
2. To get more information about the behavior of the cholesterol level of an individual,
this study provides more insight about its understanding. It is interesting to note that
the risk for high cholesterol depends heavily on gender and ethnicity.
3. It has been noticed that people above 60 years of age are more at risk which is true for
both males and females.
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Chapter 4
A Longitudinal Study of Serum Cholesterol Levels
4.1 Longitudinal Data
The observations collected repeatedly from the same unit over time in a prospective cohort
study is a longitudinal data. Multiple measurements are taken into consideration from each
individual at different times. Our aim in the present investigation is to study the changes of
the response variable or variables of interest over time and its’ association with treatments
and other covariates. That is, the objective is to describe how the response changes over
time and how these changes depend on the given characteristics of the individuals. The
goal in our study is using longitudinal data to characterize the changes with respect to time
and the factors that affect the changes. We are working with clustered data that consists of
repeated measurements obtained from units at different occasions or time points. We also
want to use this data to distinguish among different sources of variation. A longitudinal data
analysis (LDA), which includes baseline measurements that increases the efficiency and
explains the baseline variability. An important aspect of this type of data is to characterize
the changes of the response variable over time, the effect of the baseline covariates, and
among subject variation to the response.
4.2 Linear Mixed Model for Longitudinal Data
Linear mixed models (LMM) are popular procedures for analyzing repeated measurements
and clustered data. In the present study, the model includes the correlation through the
inclusion of random effects that are routinely assumed to be normally distributed [68–71].
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Several methods have been proposed in the literature to replace the normality assumption
for random effects [31, 72, 73]. Normality of within individual deviations may be a rea-
sonable model for many problems involving continuous measurements. However, in other
situations the normality assumption on a transformed scale is better but it offers challenges
in interpreting the data. We can study the change in the variable of interest over time either
at the population level or the individual level through a longitudinal study. Such a study
allows us to separately estimate the cross sectional effects and longitudinal effects. The
longitudinal study is more powerful to detect the association of interest than cross sectional
study and provides more insight for our interpretation.
In the present study there is only one response for each subject and responses are as-
sumed to be independent, which is the key assumption for classical regression models.
However, since the observations are collected from the same subject repeatedly and they
tend to be similar and dependent in our longitudinal data analysis. Although observations
collected from different subjects are still assumed to be independent. Ignoring dependency
of observations taken from the same subject implies ignoring the correlation which could
lead to invalid inference. To take care of the dependent property of longitudinal data, linear
mixed models are used where the random part addresses the correlation structure.
The linear mixed-effects model is probably the most widely applied method for ana-
lyzing longitudinal data [74–82]. It is useful for hierarchical or clustered data that can
be traced back to ANOVA paradigm which is useful to analyze longitudinal data [83]. The
method includes allowing certain regression coefficients to vary randomly across individual
to individual. This idea leads to a two-stage approach of analysis in longitudinal data. The
two-stage approach of analyzing longitudinal data has been greatly researched by various
article in literature [84, 85]. Since measurements are taken under different situations which
are not under control in general, there is a likelihood of considerable variation among indi-
viduals. These variations are handled through the random effects approach. Hence, random
effects are subject to specific explanation between subject variation and its correlation.
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A linear mixed model (LMM) is an extension of a linear regression model to model
correlated (longitudinal) data. It has two main components fixed effects and random com-
ponents. The covariate effects that are fixed across subjects in the study are considered as
the fixed effects. If we are to fit a simple linear regression model for each individual profile,
the regression coefficients in the classical regression models are fixed effects. The fixed ef-
fects explain the expected values of the observations. That is, a simple linear regression
model is given by
y = β0 + xβ +  (4.1)
where β0 is the population intercept, β is the population slope of the regression line, and 
is independent error term,  ∼ N(0, 1). βo and β are estimated by the least square method
or maximum likelihood estimators. The covariate effects that change among individuals is
called the random effects. Since these values are subject specific, they are considered as
random, that is, each subject is a random subject from the population. The random effects
explain the variance and covariance of the observations, [85], such a model is written by.
yij = β0 + β1xi,j + · · ·+ βpxij + bi + ij, (4.2)
where β’s are fixed effects of interest, bi ∼ N(0, σ2b ) are random effects, and  ∼ N(0, σ2 )
are independent errors. The bi represents the deviation of the intercept of individual “i”
from the population intercept β0. The σ2b is the variance between the subjects and σ
2
 is the
variance within each subject. Hence, the total variance of y becomes V ar(yij) = σ2b + σ
2
 .
The expected (average) increase in y with an increase in x while assuming other factors are
constant is given by:
E(yij) = β0 + β1xi,j + · · ·+ βpxij. (4.3)
The probability distribution for repeated measurements has the same form for each individ-
ual under this type of formulation. However, the parameters of that probability distribution
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vary from individual to individual. The marginal probability distribution of the repeated
measurements is a multivariate normal probability distribution with a specific covariance
structure.
4.3 Total Serum Cholesterol Level
The total serum cholesterol level is a useful screening means for consideration of lipids
in individuals younger than 50 years old. There is a direct association of the cholesterol
levels with mortality rates, [86]. There is a strong association between cholesterol levels
and coronary heart disease as well. Lowering of the cholesterol level is associated with a
reduction in coronary heart disease mortality rates, [49, 87]. Initial low serum cholesterol
levels and obesity combined appear to indicate a four times greater risk for colon cancer
than people with average values of both variables, [88]. The present study is to assess
the cause of changes of total cholesterol levels and high density of lipoprotein cholesterol
change in the adult population.
It has been discovered that coronary heart disease developed in every fifth man and every
17th woman by the age of sixty that the total cholesterol level has been shown to be an
excellent predictor of coronary heart disease in the ages less than 50 years, [89]. Studying
the cholesterol level provides crucial information about potential coronary heart disease
and other complexities in the human body. Note that various drug treatment are avoidable
for those individuals with cholesterol level 300 or above by many physicians. Necessary
therapy is suggested for individuals with cholesterol level above 250 and it is believed that
the patients, in whom, coronary heart disease will eventually develop seems to have similar
cholesterol levels, [89]. The higher the concentration of cholesterol level, the greater the
risk of coronary heart disease, [90].
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4.4 Objectives of Our Study
In the present study, we will fit a linear mixed model to analyze longitudinal total serum
cholesterol levels and investigate how it is changing over time based on age and time. Very
little research if any has been done to identify the behavior of cholesterol level over time
with age. We believe the present study strengthens the understanding of the behavior of
cholesterol level and helps to reduce the risk due to cholesterol related medical issues. The
aims of the present study is to analyze the total serum cholesterol data through frequentist
approach. We intend to analyze how the cholesterol levels change over time on the average
as people get older. Also, we wish to answer the questions: Is the change of cholesterol lev-
els associated with gender and age? How the cholesterol levels change either at population
level or individual level? Is there a significance difference between changes in cholesterol
level between males and females on the average?. We shall also explore the interaction
effects of age, gender, and cholesterol level.
4.5 Statistical Analysis
We have categorized the statistical analysis of the study in to two parts as follows.
4.5.1 Statistical Discussion of the Data
The data used in the present study was obtained from the Inter-university Consortium for
Political and Social Research and the data from the National Health and Nutrition Exam-
ination Survey (NHANS) II, 1976-1980: Serum Cholesterol data was originally collected
by United States Department of Health and Human Services.
The target population for the survey was the civilian non-institutionalized population of
the United States. The NHANES II serum cholesterol data files contain two parts of the
extensive data available. One part consists of the demographic information obtained from
household interviews and the other part is from laboratory results. The survey started in
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February 1976 and was completed in February 1980. Samples were selected so that certain
population groups thought to be at high risk of malnutrition (person with low incomes,
preschool children, and the elderly) were oversampled. Adjusted sampling weights were
then conducted for persons over the age of 76, sex, and race categories in order to inflate
the sample in such a manner as to closely reflect the estimated civilian non-institutionalized
U.S. population.
In addition to the general examination components, several more detailed examinations
were performed on subsamples of the population. The information relating to cholesterol
level in NHANS II survey considered codes 355-357. Primary site codes were 1 and 2 for
males and females, respectively. They illustrated semi-parametric approach on repeated
cholesterol data from randomly selected individuals. The data consists of participants’
cholesterol levels measured at the beginning of the study and then every 2 years for 10
years, age at baseline, and gender. The following diagram shows the data that was used in
our study.
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96
Figure 16.: Schematic Diagram of Total Number of Individuals by Gender
Summary of the basic statistics of cholesterol level measured for each time of an individ-
ual is presented, Table 7 below. It shows that the minimum cholesterol level is fluctuating
over time. A careful review, we discovered that the quartiles as well as the average choles-
terol level over time is increasing with age. However, there is no visual difference in mean
and median cholesterol level of an individual.
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Table 7: The Summary of Cholesterol Data
Min. 1st Q. Median Mean 3rd Q. Max. NA
time1 133 191 213 219.5 247.5 340
time2 150 195 217 224.2 246 360
time3 129 200 227 231.7 257 380
time4 144 209.2 232.5 238.9 264 403 8
time5 144 209 235 242.1 270 430 7
time6 153 220 243 249.3 277.5 378
age 31 36 41.5 42.49 48 62
We also notice that the maximum cholesterol level is also increasing upward with age
which is true for both males and females. Since there are about seven and eight missing
data points, we perform a t-test both (pooled and Satterthwaite) and fail to reject the null
hypothesis that there is no difference in population means for missing and non-missing age
groups at 5% level of significance.
Table 8 below shows the correlation among cholesterol levels for different times that the
observations have been measured. As observations are collected from the same individual
over time, they seem to be highly correlated. We have observed strong positive correlation
among the responses.
Table 8: Correlation Table of Cholesterol Data
time1 time2 time3 time4 time5 time6
time1 1
time2 0.673931 1
time3 0.784145 0.754992 1
time4 0.711845 0.707773 0.801818 1
time5 0.711208 0.731132 0.812008 0.803965 1
time6 0.660881 0.64175 0.728224 0.815582 0.76791 1
We are considering the longitudinal data of cholesterol level of 200 individuals. The
data consists of participants’ cholesterol measurements every two years for 10 years. The
purpose of such data is to characterize the change in cholesterol level over time, and among-
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Figure 17.: Longitudinal Cholesterol Level with Trajectories for 8 Random Subjects
subject variation in cholesterol. Figure 17, Figure 18, and Figure 19 show that cholesterol
level increases over time for most subjects but substantial inter-subject variation. The pa-
rameter estimates for fixed and random effects are given in Table 13. Note that the test of
fixed effects on the model came to be significant at 5% level of significance.
A spaghetti plot of the cholesterol data explain that the cholesterol level of an individual
over time is some what similar across the individuals regardless of age or gender. Some
of the individuals have unusual trajectory line with erratic changes. Detail analysis of the
data will give us more insight of the information. Sample plot of randomly selected eight
individuals provides us more visual insight about the nature of the data. It explains more
clearly that there is a random slope and intercept which suggests in adapting linear mixed
effects model as shown in Figure 17. It depicts that there is a variation of cholesterol level
over time for each individual and suggests that cholesterol level increases almost linearly
over time for most of the subjects with different inter-subject variation. In other words, each
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subject seems to have his/ her own trajectory line with a possibility of different intercepts
and slopes suggesting possibly two types of variation simultaneously called within and
between variations.
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Figure 18.: Box Plot of Cholesterol Data
The box plot, Figure 18 and mean trend graph, Figure 19, of cholesterol level also indi-
cate that there is a change in slope and intercept over time suggesting that the mixed effect
model might explain its behavior. Over all, there is two way variation of cholesterol level.
Each subject has on average of 5 observations and the data is not balanced because some
of the data are missing.
To explore the nature of the data more closely, we fitted simple linear regression over
time individually. We found that the pooled residual plot follows approximately normal
probability distribution which agrees with the assumption of within individual normality.
Figure 20, shows the cholesterol level for individuals over time. It has been shown in the
literature that the inference on fixed effects appears to be robust even for non normality of
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Figure 19.: Average Cholesterol Level Over Time
Figure 20.: Histogram of Subject Specific Intercepts in Simple Linear Reression
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random effects, [73, 91].
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Figure 21.: Interaction Plot
We fitted a simple linear regression considering cholesterol as response and their cor-
responding time point as covariates. A summary of the statistics for intercept and slope
for individual regression line shows that there is a difference in variances of intercept and
slope. Intercepts for individual regression has mean cholesterol level of around 221 with
high standard deviation of around 42 which explains that there is high variation among the
individuals cholesterol levels. At the same time, there are slopes with mean 2.55 with stan-
dard deviation of 3.63 indicating there is a variation of slopes as a random effects, Table
9.
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Table 9: Summary of Slopes and Intercepts
Variable N Mean Std. Dev. Sum Minimum Maximum
Intercept 200 220.6894 41.68917 44138 141.1429 360.1667
Slope 200 2.55025 3.62947 510.0506 -14 11.74286
4.5.2 Statistical Modeling of the Data
The general form of the linear mixed effects statistical model is given by
Y = Xβ + Zb+ , (4.4)
Y ∼ N(µ, V ), where Y is the response vector, µ is the mean vector, and V is the variance
covariance matrix. X and Z are fixed and random design matrices, respectively. Also, β
is a vector of unknown fixed effects, b ∼ N(0, σ2b ) is an unknown random effects, and
 ∼ N(0, σ2 I) is the unknown random independent errors. The expected value of Y is
given by
E(Y ) = Xβ = µ,
and the variance by
V ar(Y ) = V ar(Zb+ ) = ZV ar(b)Z ′ + V ar() = ZGZ ′ +R = V,
whereR = σ2 I andG = σ
2
b . Y is k - dimensional random response vector that may include
repeated measures of the same variable or measurement of correlated variables. X and Z
are known k×p and k×q matrices of covariates, β is p-dimensional vector of fixed effects,
b is q-dimensional vector of random effects, and R is a k× k covariance matrix, and G is a
p× q covariance matrix. Treating bi as random variable so as to insure the inference for the
whole population from which the sample is drawn. The correlation between yi,j and yi,j′ is
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given by:
Cor(yi,j, yi,j′) =
σ2b
σ2b + σ
2

= ρ. (4.5)
The analytical statistical model in this study is given by:
cholestlevelij = β0 + β1 ∗ timei,j + β2 ∗ genderi + β3 ∗ agei
+ β4 ∗ timei,j ∗ agei + β5 ∗ timei,j ∗ genderi
+ b0,i + b1,i ∗ timei,j + i,j. (4.6)
4.5.3 Covariance Structures for RepeatedMeasurements: Development of theModel
The covariance structure for the random behavior within subject effects which is also called
repeated measurements, is challenging considering non independence and is defined by a
series of k × k within subject covariance matrices. We model matrix “V” by setting up
the random effects design matrix Z and by specifying covariance structure for G and R.
We denote it by sigma (Σ) where k represents the number of times the subject is observed.
The covariance structure incorporates the error structure of marginal residuals as they are
defined at individual observation levels. Given below are some of key entities in the devel-
opment of the proposed statistical model, that is, unstructured (UN), variance components
(VC), compound symmetry (CS), first order autoregressive (AR (1)), and toeplitz (TOEP),
etc. Given below is a brief summary of its’ structure.
1. Unstructured (UN)
The elements of the matrix are assumed to be different in this covariance structure.
It requires maximum parameters to be estimated. The number of parameters to be
estimated is given by the relation k(k+1)
2
, where k is number of repeated measurements.
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The elements in the covariance matrix are represented by σij = σji, that is,
Σ =

σ211 σ12 · · · σ1k
σ12 σ
2
2 · · · σ2(k−1)
...
... . . .
...
σ1k σ2(k−1) · · · σ2k

. (4.7)
2. Variance Components (VC)
This structure assumes that the correlation of errors within a subject is zero and the
covariance matrix is given by
Σ =

σ21 0 · · · 0
0 σ22 · · · 0
...
... . . .
...
0 0 · · · σ2k

. (4.8)
3. Compound Symmetry (CS)
Compound symmetry assumes homogeneous variances and constant correlation regard-
less of how far apart the measurements are. It also requires that the two parameters to
be estimated in the statistical modeling. The elements in matrix form are represented
by
σij =
 σ
2
1 + σ
2, i = j
σ21, elsewhere
(4.9)
Σ =

σ2 + σ21 σ
2
1 · · · σ21
σ21 σ
2 + σ21 · · · σ21
...
... . . .
...
σ21 σ
2
1 · · · σ2 + σ21

. (4.10)
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4. First Order Autoregressive AR(1)
This covariance structure assumes homogeneous variances and exponentially declining
correlations as a function of distance. It implies that the two values that are close to
each other are highly correlated and less correlated as the measurements are farther
apart. It requires two parameters to be estimated and the elements in the matrix are
represented by σij = σ2ρ|i−j|, as follows,
Σ =

σ2 σ2ρ · · · σ2ρk−1
σ2ρ σ2 · · · σ2ρk−2
...
... . . .
...
σ2ρk−1 σ2ρk−2 · · · σ2

, (4.11)
where σ represents the variance of responses and ρ represents their correlation.
5. Toeplitz (TOEP)
This structure of covariance is similar to AR(1) which assumes that all the measure-
ments next to each other have the same correlation, the measurements that are two apart
have the same correlation, different from the first, the measurements that are three apart
have the same correlation different from first two and so on. It requires that “k” param-
eters to be estimated, the elements of the matrix can be represented by, σij = σ|i−j|+1,
and the covariance matrix is given by
Σ =

σ2 σ1 · · · σk
σ1 σ
2 · · · σk−1
...
... . . .
...
σk σk−1 · · · σ2

. (4.12)
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4.5.4 Estimation in Linear Mixed Model (LMM)
Estimating the parameters is more difficult in the linear mixed model than the linear model
because of not only we need to estimate β but also the unknown parameters in b, Z, and R.
Generalized least square (GLS) method is used to estimate the parameters by minimizing
(Y − Xβ)′V −1(Y − Xβ). There are mainly two approaches of estimating the necessary
parameters. Let Yi ∼ N(Xiβ, V ) and then the probability density function of Yi is given
by
f(Yi) = (2pi)
−n
2 |V |− 12 e− 12 (Yi−Xiβ)′V −1(Yi−Xiβ)
where i = 1, 2, ...,m. Given below are the two statistical methods of obtaining estimates
of the parameters in the proposed model.
1. Maximum likelihood estimator (MLE) method:
We have the likelihood function:
L(β, V ;Y ) =
m∏
i=1
f(Yi)
=
m∏
i=1
(2pi)−
n
2 |V |− 12 e− 12 (Yi−Xiβ)′V −1(Yi−Xiβ)
= (2pi)−
nm
2 |V |−m2 e− 12
∑n
i=1(Yi−Xiβ)′V −1(Yi−Xiβ).
Setting
D =
n∑
i=1
(Yi −Xiβ)′V −1(Yi −Xiβ),
the log-likelihood function is given by:
logL(β, V ) = −nm
2
log (2pi)− m
2
log(|V |)− 1
2
D.
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Taking the partial derivative with respect to β and letting equal to zero, that is,
∂logL(β, V )
∂β
= 0,
the maximum likelihood estimator of β and b are given by
βˆ = (X ′iVˆ
−1Xi)−1XiVˆ −1Y
and
bˆ = GˆZ ′Vˆ −1(Yi −Xiβˆ).
2. Restricted maximum likelihood estimator (REML) method:
Based on Bayesian approach, we proceed to assume a uniform prior for β. Thus, the
likelihood function is given by
L(V ;Y ) =
∫
L(β, V )dβ,
where
L(β, V ) = (2pi)−
n
2 |V |− 12 e− 12 (Yi−Xiβ)′V −1(Yi−Xiβ).
After integrating out over β, we obtain
L(V ) = (2pi)−
1
2
(n−r)|V |− 12 |X ′iV −1Xi|−
1
2 e−
1
2
(Yi−Xiβˆ)′V −1(Yi−Xiβˆ).
Now the log-likelihood function is given by
logL(V ;Y ) = −n− r
2
log(2pi)−1
2
log |V |−1
2
log |X ′iV −1Xi|−
1
2
(Yi−Xiβˆ)′V −1(Yi−Xiβˆ)
where “r” is the rank of design matrix X. Taking partial derivative of the log-likelihood
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and equating it with zero, that is,
∂ logL(V ;Y )
∂V
= 0.
There is no closed form solution to the resulting equation and we proceed to obtain
numerical approximations. We consider some reasonable estimate for V to estimate G
and R. The approximate restricted maximum likelihood or residual maximum likeli-
hood estimator of V by solving the equation given by
βˆ = (X ′iVˆ
−1Xi)−XiVˆ −1Y.
4.5.5 Model Selection
We have considered graphical representation to visually identify possible random effects,
Figure17. Akaike Information Criterion (AIC) and Bayesian Information Criterion
(BIC) have been used to select the best model. The AIC criteria is given by
AIC = −2
{
l(βˆ, θˆ; y)− q
}
, (4.13)
where βˆ is an estimate of β, θˆ is an estimate of θ, q represents number of elements in θˆ.
The smaller the AIC, the better the statistical model. And the Bayesian Information Criteria
(BIC) is given by
BIC = −2
{
l(βˆ, θˆ; y)− 0.5× q × log(m)
}
, (4.14)
where m represents number of subjects. Here, again, the smaller the BIC, the better the
statistical model.
We have fitted the linear mixed model considering different variance structures and
adopted AIC and BIC criterion to select the best possible model. The smaller the AIC
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and BIC, the better the fit. We have found that the model with unstructured G matrix with
V matrix VC appears to be the best fit for the data under RMLE method of estimation
to select the best model. Once the model that best fit the data has been identified, we esti-
mated the parameters under MLE method. We perform likelihood ratio test of the proposed
model which appears to be significant at the 5% level of significance and the test result is
presented in Table 10, below.
Table 10: Test of the Model
Source DF Sum of square Mean square F-value Pr > F
Model 214 1811887 8466.763 17.99 0.0001
Error 829 390173 470.655
Total 1043 2202060
We have observed that an interaction exists among the covariates under modeling, Figure
21, which strongly suggests that there is an interaction with time. The mean cholesterol lev-
els for male and female appear to be different. We perform analysis of variance (ANOVA)
test to identify if means of groups are equal of the population level. We are able to reject
the null hypothesis at α = 7% level of significance and conclude that there is a significance
difference in population means in groups, Table 11.
Table 11: Test for Time and Gender Effect
Source DF Sum of square Mean square F-value Pr > F
Time 5 106553.8 21310.76 45.28 0.0001
Gender 1 1399.88 1399.88 1.97 0.0694
Gender*time 5 10626.24 2125.247 4.52 0.0005
Age*time 6 157464.7 26244.12 55.76 0.0001
Id(gender) 197 1535843 7796.156 16.56 0.0001
We have considered time, age, gender, time*age, and time*gender as a fixed effects in
the modeling. We test the hypothesis that fixed effects are zero and we were able to reject
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the null hypothesis at α = 7% level of significance and concluded that they are non zero.
The test results are given by, Table 12.
Table 12: Test of Fixed Effect
Effect Num DF Den DF F Value Pr > F
Time 1 175 43.49 0.0001
Age 1 184 40.99 0.0001
Gender 1 192 3.34 0.0694
Time*age 1 176 18.87 0.0001
Time*gender 1 178 16.22 0.0001
The estimated parameters from the proposed model for fixed effects are displayed in
Table 13.
Table 13: Estimated Parameters for the Model for Fixed Effect
Effect Estimate Standard Error DF t - Value Pr > |t|
β0 123.09 15.1493 181 8.13 0.0001
β1 8.9267 1.2652 174 7.06 0.0001
β2 9.8800 5.4101 192 1.83 0.0694
β3 2.1761 0.3399 184 6.40 0.0001
β4 -0.1221 0.02811 176 -4.34 0.0001
β5 -1.8083 0.4491 178 -4.03 0.0001
Thus, the final form of the proposed statistical model is given by
cholestlevelij = 123.09 + 8.9267 ∗ timei,j + 9.88 ∗ genderi + 2.1761 ∗ agei
− 0.1221 ∗ timei,j ∗ agei − 1.8083 ∗ timei,j ∗ genderi
+ b0,i + b1,i ∗ timei,j + i,j. (4.15)
The test of the model is significant at α = 5% level of significance which indicates that
we have a good fit model to the data. After identifying the best fitted model, we performed
the residual analysis of the model. We perform Pearson residual check for residuals Figure
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(24) and Figure (25) and studentized residual check for residuals of the model, Figure (22)
and Figure (23). The residuals appear to be around zero without any pattern that will indi-
cate there is no correlation. Also, most of the residuals are within two standard deviations
away from mean zero suggesting that we have a good model for the subject data. Q-Q plot
and summary of residuals with density curve further support this claim. Equation (4.16)
provides the estimated unstructured variance covariance matrix in modeling where diago-
nal elements represent variance of cholesterol level in a particular time and off diagonal
elements represent their corresponding covariances as given below in the equation (4.16).
V =

Time1 Time2 Time3 Time4 Time5 Time6
1435.92 1063.01 1125.05 1187.09 1249.14 1311.18
1063.01 1572.6 1212.28 1286.92 1361.56 1436.2
1125.05 1212.28 1734.47 1386.75 1473.98 1561.22
1187.09 1286.92 1386.75 1921.54 1586.41 1686.24
1249.14 1361.56 1473.98 1586.41 2133.79 1811.25
1311.18 1436.2 1561.22 1686.24 1811.25 2371.23

. (4.16)
The covariance matrices of the random effects is obtained for female (Gf ) and male
(Gm) respectively are given by:
V ar(Gf ) =
1380.39 −2.2097
−2.2097 1.4663
 (4.17)
and
V ar(Gm) =
1000.96 31.0216
31.0216 3.1487
 . (4.18)
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Figure 22.: Studentized Residuals of Cholesterol Level (I)
Then, we used this information to structure the final form of the proposed model, (4.15).
The linear mixed models provide flexible tools for analysis of multiple correlated response
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Figure 23.: Studentized Residuals of Cholesterol Level (II)
variables. The model we adopted is based on fitting separate LME models for each re-
sponse, while we combine them in a single model by imposing a joint multivariate distri-
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Figure 24.: Pearson Residuals of Cholesterol Level (I)
bution for error terms.
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Figure 25.: Pearson Residuals of Cholesterol Level (II)
Figure (26) shows that the fitted values represent the observed values quite well in gen-
eral, which attempts to the quality of the model.
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Figure 26.: Observed and Fitted Cholesterol Level for Six Random Subjects
Hence, the behavior of cholesterol level of patients can be explained through mixed sta-
tistical model approach is quite reasonable. In our work, we established that the proposed
statistical model, equation (4.15), can be adapted once the baseline covariates are known.
Note that the cholesterol level of a patient changes overtime and it changes within a patient
as well as between patients. We also notice that a change in cholesterol level is different
for male and female over time as patients get older [49]. The raise in total cholesterol level
among healthy young men and women are significantly associated with age with obesity
[92]. The National Institutes of Health Consensus Development Conference on Lipid Low-
ering has recommended that cholesterol levels to be reduced to 200 mg/dl in all persons
[89].
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We have found that interaction, between age and time are significant contributors. It
suggests that age and time independently may not be contributing heavily. However, their
joint effect could have a different impact in order to develop coronary heart disease. Our
results are consistent with the result stated in similar study [90]. Similarly, age effect
in conjunction with gender could lead to high risk of developing high cholesterol level
since the mean trend cholesterol level for male and female are different, Figure 21. Since
coronary heart disease developed at a much lower rate in young women than it did in men
[89]. However, there could be a symptom complex in both genders with triglycerides which
is assumed to be closely related to coronary heart disease.
The risk of coronary heart disease in persons younger than age 50 is highly related to
total serum cholesterol levels. Increase in cholesterol level more than usual limit increases
risk of coronary heart disease five times [93]. The high cholesterol level is also strongly
related to an incidence of diabetes mellitus that is twice the rate in general population
and are usually is due to obesity or overweight [89]. Cholesterol lowering interventions
have helped to reduce coronary heart disease [94]. Since average cholesterol levels for
male appears to be higher than female and so does an increased risk in proportional to
antecedent serum cholesterol, male tend to be more at risk than female in order to suffer
from cholesterol related issues [64]. The effect of interaction of cholesterol level with age
and gender have strong association as we noticed in our study and similar to the findings in
[95].
In particular, the physical and mental health components are highly affected by choles-
terol level given to a person, for which we will be able to have prior information about the
cholesterol level which can lead us to have some precautionary measure ahead of time to
avoid any unforeseen situation, because of increased cholesterol level in the body. It is es-
sential to study the effect of cholesterol level taking other factors like diabetes, triglyceride,
and lipid into account.
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4.5.6 Contribution
In this study, we have observed interesting behavior of average cholesterol level of an
individual. We would like to list some of the important findings.
1. The average cholesterol level increases linearly as an individual get older posing the
high risk of getting cholesterol related diseases.
2. Each individual has its own trajectory of increasing average cholesterol level as she/he
gets older and it is true for both males and females.
3. There is a inter person variation of average cholesterol level which suggests that indi-
viduals’ cholesterol level could be above or below from marginal cholesterol level.
4. Our study shows that there is an interaction between time with age and gender. That
suggests that time with age and gender plays important role in identifying the effects of
cholesterol in an individual.
5. Finally, we developed a statistical model that takes into consideration all significant
attributable variables and interactions. Thus, one can use this model to estimate the
cholesterol level of an individual, among other important information.
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Chapter 5
Modeling Serum Cholesterol Levels by Functional Data Analysis Approach
5.1 Functional Data
Functional data is multivariate data with an ordering on the dimension (Muller, 2006).
Functional data analysis is all about the analysis of information given by curves, [96, 97].
The observations are converted into a curve that is computable for any argument and the
curve would be the input for functional data analysis. Functional data is represented by a
set of basis functions that are the functional building block which are combined linearly to
represent the statistical model. Spline basis, Fourier basis, constant basis, and exponen-
tial basis, etc, are some such examples. The basis functions are mathematical functions
used to represent the observed data as a curve. If these observations are assumed to have
no error, the process is interpolated otherwise the data needs to be separated by error and
is called smoothing. The general purpose of the functional data analysis is to represent
the data into different ways to produce relevant statistical analysis, that is, display the data
so as to highlight its different characteristics and patterns it represents, and to explain the
variation of an outcome with the help of the attributable variables, [98, 99].
5.2 Introduction
Coronary heart disease (CHD) is one of the leading cause of deaths in the USA, [49].
Smoking, high blood pressure, and high cholesterol level are the most clearly established
risk factors that have been identified as being strongly associated with coronary heart dis-
ease, [48]. Total serum cholesterol level (SCL) is a major risk factor for CHD among them.
72
CHD is responsible for more deaths than all forms of cancer combined, [49]. A general
criteria has been in practice that total SCL for adults should be below 200mg/dl and in-
dividuals with values between 200mg/dl to 239 mg/dl should be considered as borderline
high risk; those with values more than 240 mg/dl should be regarded as high risk for CHD,
[51, 52]. Hence, it is extremely important to understand the SCL behavior so as to reduce
its associated risks.
It has been well established that diets and drugs play a crucial role in SCL, [53, 54].
The behavior of cholesterol under controlled diets and drugs are presently under intensive
research, [61, 100], since diet and cholesterol level are highly correlated. Significant efforts
have been also made to predict the cholesterol level based on the age and gender, [58, 59].
Males and females seem to have a different relationship in the prediction process. Very
little work has been done about modeling the cholesterol level with respect to males and
females, until the present study.
In this study, we have modeled the cholesterol data for males and females for USA, in-
dividually through functional data analysis approach to understand the behavior of choles-
terol levels. Functional data analysis is an important analytical method that can be used
for exploratory and hypothesis driven analyses. A primary advantage in using functional
data analysis (FDA) is the ability to assess continuous data that change over time and it
represents each curve that is given by a function. Our study provides us with important
information about the relationship among gender, age, and average cholesterol level of
individuals.
5.3 Data Source
The data utilized in the present study was made available by the inter-university Consor-
tium for Political and Social Research and the data for the National Health and Nutrition
Examination Survey (NHANS) II, 1976-1980: Serum Cholesterol was originally collected
by United States Department of Health and Human Services.
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NHANS II was conducted on a nationwide with approximately 28,000 persons. The tar-
get population for the survey was the civilian non-institutionalized population of the United
States. The NHANES II serum cholesterol data files contain two parts of the extensive data
available. One part consists of the demographic information obtained from household in-
terviews and the other part is laboratory results. The survey started in February 1976 and
was completed in February 1980. Samples were selected so that certain population groups
thought to be at high risk of malnutrition (person with low incomes, preschool children,
and the elderly) were oversampled. Adjusted sampling weights were then conducted for
persons over the age of 76, sex, and race categories in order to inflate the sample in such a
manner as to closely reflect the estimated civilian non-institutionalized U.S. population.
In addition to the general examination components, several more detailed examinations
were performed on subsamples of the population. Our study includes 11,864 persons
for SCL cases with 9,602 males and 2,262 females. The information relating to SCL in
NHANS II survey considered codes 355-357. Primary site codes were 1 and 2 for males
and females, respectively. The following diagram illustrates the data that we are using in
the present study.
Cholesterol
Data
11,864
Male
9,602
Female
2,262
Figure 27.: Number of Individuals in the Study by Gender
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5.4 Statistical Model
The functional data and parameters are usually assumed to be, at least implicitly, smooth or
regular. This implies that there exist certain numbers of derivatives which are sufficiently
smooth. The first step in functional data analysis (FDA) is to transform the available time
series data into functions. The functions are represented as a linear combination of a set
of basis functions φk, k = 1, 2, ..., K which are considered as a set of functional building
blocks. The function x(t) defined in this manner is expressed in mathematical notation as
x(t) =
K∑
k=1
ckφk(t) = c
′φ(t), (5.1)
and is called a basis function expansion. The parameters c1, c2, ..., ck are the coefficients
of expansion. The matrix expression in the last term of equation (5.1) uses c′ to stand
for the vector of K coefficients and φ denotes a vector of length K containing the basis
functions. We have considered Fourier basis system during our modeling but we did not
obtain satatisfactory results. As the number of basis functions increases the model can yield
a better fit to the data.
The smoothing process is a statistical procedure that reduces the variance of the data
without significantly affecting the structure of the data. Functions can be smoothed by
minimizing the number of basis functions using the roughness penalty approach. This
approach uses a large number of basis function but at the same time smoothness using
penalizing process results in difficulty to measure the function complexity. More basis
functions relative to data points can cause over fit whereas less basis functions may have a
risk of losing functional features. In the present study we have smoothed the data using a
harmonic acceleration roughness penalty that penalizes departures from a shift given by
x(t) = c1 + c2Sin(2pit/365) + c3Cos(2pit/365), (5.2)
where c1, c2, c3 are Fourier coefficients.
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A multiple of the smoothness penalty is applied to the error sum of squares (SSE) to
produce the desired smooth curve. The generalized cross validation measure (GCV) devel-
oped by Craven and Wahba, [101], is designed to locate the best value for smoothing the
parameter λ which is used to specify the degree of penalty. The fit of the function to the
observed data improves as λ approaches zero. In our study, we have obtained a λ = 0.1.
The selection of value of λ is based on achieving mean square error. Thus, the generalized
cross validation measure is given by
GCV = (
n
n− df(λ))(
SSE
n− df(λ)). (5.3)
Here λ is a smoothing parameter. This model has been selected based on root mean square
values. The less the root mean square the better the fit. The selected model has root mean
square of 1.7. We consider penalized square error (PENSSE) that will minimize the error
so as to obtain a better fit function is given by
PENSSE = Σni=1(yi − x(ti)2 + λ
∫
[D2x(t)]2dt. (5.4)
Here x(t) measures the roughness of x, λ is a continuous tuning (smoothing) parameter
that trades off the fit to yi and roughness and it should be chosen appropriately, and D is a
differential operator. As λ increases, roughness is increasingly penalized and x(t) becomes
smooth and vice versa.
5.5 Result
Cholesterol level by sex and race was investigated. Distinctively different cholesterol lev-
els may have important implications in identifying the risk factors associated with it and its
treatment. Pairwise comparisons was performed to determine if the mean response of each
group is the same non-parametrically. The mean cholesterol levels of males and females
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for overall behaviors were investigated. We used the Mann-Whitney-Wilcoxon, a non para-
metric test in order to identify whether or not the males and females cholesterol levels are
the same. The hypothesis was rejected at α = 5% level of significant that male and female
cholesterol levels were coming from two identical populations (p-value=4.8e-09). Since
non parametric statistical test suggests that male and female cholesterol data are from two
different populations, it was therefore, crucial to investigate males and females separately.
Figure 28.: Mean Cholesterol Level of Male with Respect to Ages (Years)
Figure (28), depicts the average cholesterol level of males that increases as age increases
until the age of 60 years old and then decreases till the age of 70 years old. It again increases
at the age of 80 years old. Notice that cholesterol levels seem to be increasing linearly from
the late teen to 80 years of age. We also observed that after the age of 80, cholesterol levels
are unstable and seems to decrease significantly to nearly 210 gm/dl. It appears that the
cholesterol level seems to decrease rapidly for 80 years and above.
Figure (29) explains that the average cholesterol level behavior of females seems to fol-
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Figure 29.: Mean Cholesterol Level of Female with Respect to Ages (Years)
low the same pattern as males but at a higher rate. The average cholesterol level increases
as age increases up to age of 60 years old and then decreases. It again increases slightly
after the age of 80 years and then decreases continuously. The cholesterol level for females
appears to be lower than that of males after the age of 80 years on the average. Average
cholesterol levels of females appears to increase linearly from the late teen up to the age of
60. The average cholesterol levels for females appear to be volatile after the age of 70 years
old. We also observed that the average cholesterol level changes slightly in males as well
as females at the age of late 40’s or early 50’s years of age. However, it starts increasing
afterwards indicating some kind of association with age in general.
5.6 Discussion
The cholesterol levels for both males and females seems to be well within the limits with
respect to the health of an individual within the age of 30 years old. An individual is more
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active physically and mentally might have played important role to maintain a balanced
cholesterol despite the disparity of their dietary habits for males and females. We have
observed that the cholesterol level becomes more volatile as people get older, most notably
above the age of 60 years old. It has been found that cholesterol level develops from late
teens to mid-40s [62, 63] in an individual. The risk of high cholesterol and heart disease
increases with age, and men over 45 years old are most at risk. We have observed that
the average cholesterol levels for males and females are significantly different throughout
the ages, [63]. The higher the cholesterol level an individual has, the greater the risk of
developing heart disease like coronary heart disease, heart attack, and stroke. The effect
of cholesterol level is extensively discussed in a well-known study called Framingham
Study, [64]. Since the average cholesterol level of females appears to be relatively more
than males, it might be possible that females are more at risk in developing disease related
to cholesterol levels. However, researchers have noticed that gender-related changes in
insulin resistance is important in adolescents, and found that insulin resistance was more
frequent in males than females. The insulin resistance was associated with a decrease in
good cholesterol and an increase in triglycerides. This makes males more vulnerable than
females.
Any recommendation based on males information can not be generalized to females and
vice-versa. This study may assist in developing guidelines which will better provide physi-
cians and public health practitioners, when determining how to treat their patients, depen-
dent upon gender and age. The results of this study will inform individuals in preventing
premature deaths, [49], possibly due to heart attacks and strokes. In our study we noticed
the significant difference between the average cholesterol levels of males and females, that
is also supported by [102]. More specific detailed study is required to identify the specific
causes that lead to differences in cholesterol level in males and females. Since cholesterol
level is highly dependent on eating habits, attitude, and life style, more careful study about
these factors are essential to understand their actual associated risks, that were also stated
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by [65, 66]. It is also recommended that we should pay attention to what we eat, especially
our choice of oils and fats, watch our weight, and stay physically active. The inferences
made without taking these factors into account may lead to misleading results and can have
serious consequences, [67]. Also, data is needed to study the family history of heart dis-
eases at younger age and cholesterol level as well. Our study may assist in designing of
new experiments to collect a more appropriate data so as to define the attributable variables
that drive the levels of cholesterol.
5.6.1 Contribution
In the present study we have presented a discussion on the role of cholesterol levels play in
a person’s health. More specifically, we can attest to the following.
1. Proved that male and female cholesterol levels are significantly different and must an-
alyzed accordingly.
2. Have identified a method, harmonic acceleration procedure that uses a roughness penalty
to smooth the function that characterizes the behavior of cholesterol levels as a function
of age and gender.
3. Have developed a statistical model in term of basis functions that characterizes the
behavior of the cholesterol level as a function of age and gender. A physician can use
the basis function curve to identify his/her patients’ behavior of cholesterol level as a
function of his/her age and gender to take appropriate action.
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Chapter 6
Future Work
In the first part of the dissertation, we have proposed the Bayesian Age - Period - Cohort
Model for Lung Cancer Mortality that explains the mortality rate due to lung cancer based
on age at death, period at death, and birth- cohort of an individual. It can explain the
mortality for different age groups, different periods, and at the same time as birth-cohort.
Histogram smoothing prior has been implemented to explain the mortality rate for different
sub populations of our interest.
To understand lung cancer completely, all the possible contributing factors are essential
to include in the analysis. We have intended to study lung cancer, including smoking and
second hand smoking, as it is well established that more than 30% of lung cancer has
been contributed by smoking. This study could provide more insight in understanding lung
cancer behavior.
In conjunction to the histogram smoothing in Bayesian modeling, we intend to study
different prior structure variance covariance matrix. The possible decomposition could
provide more flexibility for assigning the prior and enhances the more precise estimates
of parameters of interest. We have also planned to implement non parametric density es-
timates to assign a prior for covariance matrix. This approach could give a more accurate
estimate for the parameters.
In Chapter Four, We analyzed the longitudinal data through linear mixed model ap-
proach, considering summary statistics of simple linear regression for each individual sub-
ject as a new response to understand the behavior of total cholesterol level. We intend to
extend our study in non normal data as well.
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It will provide more insight about the study if we can implement the analysis for non nor-
mal random and error assumption in modeling. Since the random effect follows stochastic
properties, we could implement a stochastic approach to understand the longitudinal data.
It would be interesting to consider a Bayesian approach of linear mixed model to study
longitudinal data. Since we have observed that a handful of data missing, we intend to ad-
dress missing values by implementing EM algorithm and see how the inference is affected
by two different approaches. We are working on implementing the different approaches to
include the missing values issue in modeling longitudinal data analysis.
Data analysis through functional data analysis is a relatively new approach. It has a lot
of flexibility in modeling as it converts data into basis functions. There is an abundance
of possibilities in exploring this area in data analysis. Functional data provides access to
models of rates of change that can help to understand the rate of change of quantity in
which we are interested. It has tremendous applications virtually in every area. All the
statistical theories that have been developed in parametric analysis can possibly develop
in functional data analysis. To identify the order of derivatives under a functional data
approach modeling could be interesting to work on in the future.
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